Redcare Pharmacy stock: Berenberg raises target to EUR 102.00 for Redcare Pharmacy stock
Published on 10/21/2026 at 16:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBerenberg target raised
- Berenberg raised its target from EUR 94.00 to EUR 102.00 on October 7, 2026.
- Redcare will publish its third-quarter statement on October 29, 2026.
- Redcare Pharmacy stock costs EUR 77.55 at Lang & Schwarz on October 21, 2026, 2.11 percent above the Xetra close of October 20, 2026, and 6.23 percent below its 52-week high.
- Redcare Pharmacy had a market capitalization of EUR 1.60 billion on October 21, 2026.
Redcare Pharmacy (ISIN NL0012044747) received a higher Berenberg price target of EUR 102.00 on October 7, 2026, up from EUR 94.00, while the Buy rating was maintained, according to onvista. The note linked the higher confidence to stronger customer activity in prescription medicines. At Lang & Schwarz, the stock was trading at EUR 77.55 on October 21, 2026 at 4:03 p.m. CEST, up 2.11 percent versus the Xetra close of October 20, 2026 at EUR 75.95.
October 29 brings the next test
Redcare Pharmacy is scheduled to publish its third-quarter interim statement on October 29, 2026, together with an analyst and investor conference, according to the company announcement carried by Financial Times. That date gives the market a defined checkpoint for the prescription-revenue trend and profitability after the latest target revisions.
The stock remains below its yearly high
Redcare Pharmacy traded 6.23 percent below its 52-week high of EUR 82.70 and well above its 52-week low of EUR 30.20 on October 21, 2026. The session volume was 30,586 shares, while the market capitalization stood at EUR 1.60 billion.
How wide is the target gap?
Berenberg's EUR 102.00 target stands 31.53 percent above the EUR 77.55 Lang & Schwarz price. Redcare's trailing price-to-earnings ratio was minus 37.13 on October 21, 2026, reflecting the company's still negative earnings profile in the market data.
Comparison with peers
Redcare Pharmacy: up 2.11 percent, P/E minus 37.13, market capitalization EUR 1.60 billion.
DocMorris (SIX, CHF): unchanged, P/E minus 10.11, market capitalization CHF 798.2 million.
CVS Health (NYSE, USD): down 0.61 percent, P/E 24.88, market capitalization USD 120.4 billion.
Price remains below the 52-week high
The current level leaves Redcare Pharmacy 6.23 percent below its EUR 82.70 52-week high, while the upcoming October 29 report provides the next dated operating checkpoint. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.
Redcare Pharmacy at a glance
- Company: Redcare Pharmacy N.V.
- ISIN: NL0012044747
- WKN: A2AR94
- Ticker: RDC
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 21, 2026, 4:03 p.m. CEST): EUR 77.55
- Change versus Xetra close: plus 2.11 percent
- Xetra close (October 20, 2026): EUR 75.95
- Market capitalization: EUR 1.60 billion (as of October 21, 2026)
- 52-week range: EUR 30.20-82.70 (as of October 21, 2026)
- Sector / Industry: Healthcare / Medical Distribution
- Index membership: SDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
